Seres Therapeutics, Inc.

NASDAQ:MCRB

Biotechnology

Healthcare
$5.28 +1.70%

+$0.11 today

Market cap
$51.13M
Beta
0.11
P/E (TTM)
-1.3
EPS (TTM)
-$4.89
52W Low $5.31High $29.98

Volume 0.04M

Average 0.06M

MCRB Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Seres Therapeutics, Inc.NASDAQ: MCRB

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation declines year over year

Q1 FY2026 stock-based compensation of $1.77M fell 37.4% year over year, ahead of the -43.4% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 44.8% from the prior quarter. Over 3 fiscal years it compounded at -24.8% a year.

Context

  • Stock-based compensation amounted to 1373.9% of revenue in FY2025.
  • Stock-based compensation increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -37.4% holds above the trailing-twelve-month pace of -43.4%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.77M-44.8% QoQ
Last fiscal yearDec 2025
$10.84M-48.3% YoY
LTMMar 2026
$9.79M-43.4% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-37.4%——
1 year-48.3%——
3-year CAGR-24.8%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
10.84M USD
Year-over-year change
-48.3%
4-year CAGR
-14.4%

Stock-Based Compensation vs competitors

How MCRB compares with its peers on the latest reported figures

  • MCRB's LTM Mar 2026 stock-based compensation of $9.79M is the 2nd largest of the 9 companies compared; the peer median is $4.47M.
  • Its year-over-year change of -43.4% is the 5th highest of 8, against a peer median of -42.1%.
  • Stock-based compensation amounts to 853.3% of revenue for MCRB, versus a peer median of 33.0%.
MCRB Competitors Peer median
Stock-Based Compensation for MCRB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SEERSeer, Inc.LTM Mar 2026$12.88M -49.1%-22.9%85.6%
MCRBSeres Therapeutics, Inc.LTM Mar 2026$9.79M -43.4%-24.8%853.3%
ABOSAcumen Pharmaceuticals, Inc.LTM Mar 2026$9.77M +1.5%+47.6%—
ACTUActuate Therapeutics IncLTM Mar 2026$6.28M +111.2%+109.9%—
HURATuHURA Biosciences, Inc.LTM Mar 2026$5M —+208.8%—
IRDOpus Genetics, Inc.LTM Mar 2026$3.95M +20.1%+23.4%33.0%
SPROSpero Therapeutics, Inc.LTM Mar 2026$3.88M -47.0%-22.0%7.1%
INOInovio Pharmaceuticals, Inc.LTM Mar 2026$3.06M -44.1%-45.0%—
CGTXCognition Therapeutics, Inc.LTM Mar 2026$1.83M -42.1%-16.4%—
Peer median (excluding MCRB) $4.47M-42.1%+3.5%33.0%

Competitors are the stored peer set for MCRB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(65.58M)(250.16M)(113.72M)136K5.7M
Depreciation & Amortization5.95M6.63M6.24M5.47M4.13M
Deferred Income Tax00000
Stock-Based Compensation20.22M25.48M34.1M20.97M10.84M
Change in Working Capital41.53M(18.39M)(58.98M)(65.51M)(27.78M)
Accounts Receivables9.39M0(8.67M)(2.07M)1.55M
Inventory00(29.65M)(33.8M)0
Accounts Payables9.36M2.2M(11.58M)(2.94M)(2.4M)
Other Working Capital22.78M(20.59M)(9.08M)(26.71M)(26.93M)
Other Non-Cash Items4.57M7.62M15M(109.68M)8.23M
Operating Cash Flow6.69M(228.82M)(117.35M)(148.61M)1.12M
Capital Expenditures(9.57M)(9.82M)(7.98M)(380K)(252K)
Acquisitions (Net)0(92.25M)00210K
Purchases of Investments(95.97M)(48.22M)(4.43M)13.52M0
Sales of Investments169.63M140.47M22.98M142.67M0
Other Investing Activities092.25M0(13.52M)0
Investing Cash Flow64.09M82.43M10.58M142.29M(42K)
Debt Repayment(948K)25.7M50.52M(127.91M)0
Common Stock Issued2.13M101.17M18.16M23.53M13.9M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities2.13M2.74M3.03M14M0
Financing Cash Flow1.18M129.6M71.71M(90.37M)13.9M
Effect of Forex Changes(1K)(1K)2K(1K)0
Net Change in Cash71.95M(16.79M)(35.07M)(96.69M)14.97M
Free Cash Flow(2.88M)(238.64M)(125.33M)(148.99M)865K

Seres Therapeutics, Inc.

NASDAQ:MCRB

Intrinsic Alpha fair value

Locked

Current Price

$5.28

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.